- Conditions
- Heart Failure With Normal Ejection Fraction, Left Ventricular Hypertrophy, Aortic Valve Stenosis, Diabetes
- Interventions
- 11C-Martinostat, PET-MRI
- Drug · Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Heart Failure With Preserved Ejection Fraction, Concentric Hypertrophy
- Interventions
- Pacemaker PLR + TRT ON, Pacemaker non-pacing mode or an exertional rate-adaptive pacing mode with no planned pacing at rest.
- Device
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart Failure
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 8
- States / cities
- Naples, Florida • O'Fallon, Illinois • Springfield, Illinois + 5 more
- Conditions
- Hypertrophic Cardiomyopathy
- Interventions
- Ranolazine
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Ischemic Cardiomyopathy, Non-ischemic Cardiomyopathy, Heart Failure, Cardiomyopathies
- Interventions
- AAV1/SERCA2a (MYDICAR), Placebo
- Genetic
- Lead sponsor
- Celladon Corporation
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • La Jolla, California • Long Beach, California + 26 more
- Conditions
- Cardiomyopathy, Hypertrophic
- Interventions
- Mavacamten, Placebo
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 580 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 36 more
- Conditions
- Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Mitochondrial Cardiomyopathy, Noncompaction Cardiomyopathy, Restrictive Cardiomyopathy
- Interventions
- Not listed
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- Ventricular Ejection Fraction, LVF, LV Dysfunction, Atrial Enlargement, Conduction Defect, Heart Failure, Valvular Heart Disease, Ischemic Heart Disease, Cardiotoxicity, Myocardial Infarction, Dilated Cardiomyopathy, HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Syncope, Remodeling, Cardiac
- Interventions
- 15-minutes of sitting during COR ECG Acquistion
- Device
- Lead sponsor
- Peerbridge Health, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 8
- States / cities
- Orange, California • Pasadena, California • Detroit, Michigan + 5 more
- Conditions
- Hypertrophic Cardiomyopathy
- Interventions
- Eleclazine, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 26
- States / cities
- Los Angeles, California • Stanford, California • New Haven, Connecticut + 16 more
- Conditions
- Cardiomyopathy, Hypertrophic, Dilated Cardiomyopathy, Duchenne Muscular Dystrophy, Cardiac Sarcoidosis, Becker Muscular Dystrophy, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction
- Interventions
- Hyperpolarized 13C-Pyruvate
- Diagnostic Test
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Coronary Disease, Healthy, Hypertrophic Cardiomyopathy, Myocardial Ischemia
- Interventions
- Magnetic resonance imaging
- Procedure
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 249 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1997 – 2003
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hypertrophic Cardiomyopathy
- Interventions
- Noncontrast echocardiography, Contrast Echocardiography, Cardiac magnetic resonance imaging
- Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Hypertrophic Cardiomyopathy (HCM)
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hypertrophic Cardiomyopathy, Left Ventricular Hypertrophy, Myocardial Ischemia
- Interventions
- Losartan
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2003
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Atrial Fibrillation
- Interventions
- LARIAT LAA, WATCHMAN
- Device
- Lead sponsor
- Kansas City Heart Rhythm Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Angina, Unstable, Myocardial Infarction, Ischemic Heart Disease
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 20 Years to 75 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Heart Failure, Myocardial Infarction, Left Ventricular Hypertrophy
- Interventions
- Diffusion Tensor MRI (DTI), Gadolinium DOTA Meglumine
- Device · Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2028
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Hypertension
- Interventions
- Eplerenone, placebo
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 40 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 2
- States / cities
- St Louis, Missouri • Philadelphia, Pennsylvania
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFpEF)
- Interventions
- Personalized cardiac pacing
- Device
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart Failure
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • San Francisco, California • Hartford, Connecticut + 22 more
- Conditions
- Obstructive Hypertrophic Cardiomyopathy (oHCM)
- Interventions
- Mavacamten
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Chronic Kidney Disease, Left Ventricular Hypertrophy
- Interventions
- paricalcitol, placebo
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • Tempe, Arizona • San Diego, California + 24 more
- Conditions
- Hypertrophic Cardiomyopathy
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 5,880 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1987 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hypertrophic Cardiomyopathy
- Interventions
- Not listed
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2020
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Cardiomyopathy, Hypertrophic
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hypertension, Left Ventricular Hypertrophy, Overweight
- Interventions
- Aliskiren 150/300 mg, Losartan 50/100 mg, Aliskiren placebo, Losartan 50/100 mg placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey